Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Bioavailability of BI 1358894
NCT04426851Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bi 1358894 in major depressive disorder (MDD) and borderline personality disorder (BPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve From 0 to Infinity and Area Under the Concentration-time Curve From 0 to 312 h. Started Jul 2020; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT04426851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426851.